Jianqin Lu, BPharm, PhD

Assistant Professor, Pharmaceutics and Pharmacokinetics
Assistant Professor, BIO5 Institute
Member, NCI designated UA Comprehensive Cancer Center
Member, Southwest Environmental Health Sciences Center

Jianqin Lu, BPharm, PhD, is an Assistant Professor of Pharmaceutical Sciences in Pharmaceutics and Pharmacokinetics, at The University of Arizona College of Pharmacy. The overarching goal of the Lu lab is to apply synthetic chemistry, nanoparticle engineering, and tumor immunology to develop safe and efficacious nanotherapeutics to address the pressing unmet needs in current cancer therapy, particularly in the emerging field of combination immunochemotherapy. The Lu Lab's expertise in Pharmaceutics, Drug Delivery, Nanomedicine and Tumor Immunology paves the way to develop transformative and clinically translatable nanoimmunotherapeutics for combatting cancers. Dr. Lu was the recipient of the Norman R. and Priscilla A. Farnsworth Award at the University of Pittsburgh, and USHHS Ruth L. Kirschstein Institutional National Research Service Award in Tumor Immunology, among others.

Education & Post Graduate Training: 

Postdoc, Nanomedicine/Tumor Immunology, University of California, Los Angeles, 2019
Postdoc, Nanomedicine, The University of Chicago, Chicago, 2015
PhD, Pharmaceutics, University of Pittsburgh, Pittsburgh, 2014
BS, Pharmacy, Hunan University of Chinese Medicine, Changsha, China, 2010

Areas of Research: 

Drug Delivery
Nanomedicine
Pharmaceutics and Pharmacokinetics
Nano-ImmunoEngineering
Cancer Immunotherapy
Chemotherapy
Biomaterials

Types of Research:

Laboratory-based Research
Basic and Applied Sciences
Industry
Translational Medicine

Select Publications

2017

Liu X, Jiang J, Ji Y, Lu J, Chan R, Meng H. "Targeted drug delivery using iRGD peptide for solid cancer treatment." Mol Syst Des Eng. 2017;2(4):370-379. PMCID: PMC6258069  PMID: 30498580

2015

Lu J, Liu C, Wang P, et al. "The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin." Biomaterials. 2015;62:176-87. PMCID: PMC4470812  PMID: 26057133
He C, Lu J, Lin W. "Hybrid nanoparticles for combination therapy of cancer." J Control Release. 2015;219:224-236. PMCID: PMC4656047  PMID: 26387745

2014

Lu J, Zhao W, Liu H, et al. "An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance." J Control Release. 2014;196:272-86. PMCID: PMC4267990  PMID: 25456831
Lu J, Zhao W, Huang Y, et al. "Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier." Mol. Pharm.. 2014;11(11):4164-78. PMCID: PMC4224520  PMID: 25265550

2013

Li J, Ghazwani M, Zhang Y, et al. "miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression." J Hepatol. 2013;58(3):522-8. PMCID: PMC3619187  PMID: 23178710
Lu J, Huang Y, Zhao W, et al. "PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers." Biomaterials. 2013;34(5):1591-600. PMCID: PMC3529003  PMID: 23182923
Lu J, Huang Y, Zhao W, et al. "Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel." Mol. Pharm.. 2013;10(8):2880-90. PMCID: PMC3778165  PMID: 23768151

2012

Huang Y, Lu J, Gao X, et al. "PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel." Bioconjug Chem. 2012;23(7):1443-51. PMCID: PMC3399921  PMID: 22681537